Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01395329 · ClinicalTrials.gov registry record · Phase 4
Nebivolol and the Endothelin (ET)-1 System
A Phase 4 study, sponsored by University of Colorado, Boulder.
- Completed
- Registry status
- Phase 4
- Development phase
- 42
- Enrollment target
NCT01395329 is a Phase 4 study that has completed, run by University of Colorado, Boulder. The registered enrollment target is 42 participants.
The verdict
NCT01395329, a Phase 4 study, has completed, sponsored by University of Colorado, Boulder.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 42 participants
- Enrollment target
Study Summary
The investigators hypothesize that nebivolol will reduce ET-1-mediated vasoconstrictor tone in adult humans with elevated blood pressure to a greater extent than either metoprolol or placebo.
Interventions
- DRUG Placebo
- DRUG Nebivolol
- DRUG Metoprolol
- OTHER Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min)
- OTHER FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2011-05 |
| Est. Completion | 2016-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01395329
The ClinicalTrials.gov registry entry for NCT01395329 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Boulder, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01395329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01395329 about?
NCT01395329 is a clinical study titled "Nebivolol and the Endothelin (ET)-1 System". The investigators hypothesize that nebivolol will reduce ET-1-mediated vasoconstrictor tone in adult humans with elevated blood pressure to a greater extent than either metoprolol or placebo.
What is the current status of trial NCT01395329?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 42 participants. The study started on 2011-05. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01395329?
The interventions under investigation include: Placebo (DRUG), Nebivolol (DRUG), Metoprolol (DRUG), Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min) (OTHER), FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min) (OTHER).
Who is sponsoring clinical trial NCT01395329?
This trial is sponsored by University of Colorado, Boulder, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.